A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Corvus Pharmaceuticals, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 563,932 shares of CRVS stock, worth $4.86 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
563,932
Previous 637,032 11.48%
Holding current value
$4.86 Million
Previous $1.13 Million 9.52%
% of portfolio
0.0%
Previous 0.0%

Shares

23 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 09, 2024

SELL
$1.36 - $2.29 $99,416 - $167,399
-73,100 Reduced 11.48%
563,932 $1.03 Million
Q1 2024

May 13, 2024

BUY
$1.76 - $2.41 $87,296 - $119,536
49,600 Added 8.44%
637,032 $1.13 Million
Q4 2023

Feb 13, 2024

BUY
$1.08 - $1.92 $178,944 - $318,122
165,689 Added 39.29%
587,432 $1.03 Million
Q3 2023

Nov 14, 2023

SELL
$1.41 - $2.97 $95,781 - $201,752
-67,930 Reduced 13.87%
421,743 $616,000
Q2 2023

Aug 11, 2023

SELL
$1.0 - $3.86 $16,359 - $63,145
-16,359 Reduced 3.23%
489,673 $1.12 Million
Q1 2023

May 12, 2023

SELL
$0.65 - $0.92 $92,690 - $131,192
-142,600 Reduced 21.98%
506,032 $460,000
Q4 2022

Feb 13, 2023

SELL
$0.74 - $1.04 $241,896 - $339,962
-326,887 Reduced 33.51%
648,632 $551,000
Q3 2022

Nov 14, 2022

BUY
$0.71 - $1.17 $8,936 - $14,726
12,587 Added 1.31%
975,519 $798,000
Q2 2022

Aug 12, 2022

BUY
$0.87 - $2.03 $53,766 - $125,453
61,800 Added 6.86%
962,932 $953,000
Q1 2022

May 13, 2022

SELL
$1.46 - $2.48 $208,196 - $353,648
-142,600 Reduced 13.66%
901,132 $1.48 Million
Q4 2021

Feb 11, 2022

BUY
$2.34 - $5.31 $1 Million - $2.28 Million
429,362 Added 69.89%
1,043,732 $2.52 Million
Q3 2021

Nov 12, 2021

SELL
$1.89 - $8.53 $82,593 - $372,761
-43,700 Reduced 6.64%
614,370 $2.97 Million
Q2 2021

Aug 13, 2021

SELL
$2.46 - $3.14 $13,284 - $16,956
-5,400 Reduced 0.81%
658,070 $1.76 Million
Q1 2021

May 13, 2021

SELL
$2.86 - $4.77 $382,096 - $637,272
-133,600 Reduced 16.76%
663,470 $2.04 Million
Q4 2020

Feb 10, 2021

SELL
$3.56 - $4.86 $277,430 - $378,739
-77,930 Reduced 8.91%
797,070 $2.84 Million
Q3 2020

Nov 13, 2020

SELL
$2.6 - $5.37 $407,940 - $842,553
-156,900 Reduced 15.2%
875,000 $3.51 Million
Q2 2020

Aug 13, 2020

BUY
$2.01 - $4.05 $203,411 - $409,860
101,200 Added 10.87%
1,031,900 $2.81 Million
Q1 2020

May 14, 2020

BUY
$1.74 - $5.98 $42,630 - $146,510
24,500 Added 2.7%
930,700 $1.96 Million
Q4 2019

Feb 13, 2020

BUY
$2.56 - $5.44 $139,320 - $296,055
54,422 Added 6.39%
906,200 $4.93 Million
Q3 2019

Nov 13, 2019

BUY
$3.01 - $6.5 $56,226 - $121,420
18,680 Added 2.24%
851,778 $2.56 Million
Q2 2019

Aug 12, 2019

BUY
$3.3 - $4.58 $169,613 - $235,402
51,398 Added 6.58%
833,098 $3.12 Million
Q1 2019

May 14, 2019

BUY
$3.75 - $4.97 $447,750 - $593,418
119,400 Added 18.03%
781,700 $3.14 Million
Q4 2018

Feb 13, 2019

BUY
$3.29 - $8.94 $2.18 Million - $5.92 Million
662,300 New
662,300 $2.43 Million

Others Institutions Holding CRVS

About Corvus Pharmaceuticals, Inc.


  • Ticker CRVS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,553,500
  • Market Cap $401M
  • Description
  • Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The compan...
More about CRVS
Track Jim Simons's Portfolio

Track Jim Simons Portfolio

Follow Jim Simons (Renaissance Technologies LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.